HC Wainwright & Co. Reiterates Buy on Fennec Pharmaceuticals, Maintains $16 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 86.1%

Neg 0% Neu 86.1% Pos 0%

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and maintains $16 price target.